Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis
2023-507527-28-00Phase 2Authorised
- Sponsor
- LimmaTech Biologics
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in recurrent vulvovaginal candidiasis (RVVC) comparing Candida vaccine with Placebo (2 arms). Planned start Dec 2023; status: authorised.
02
Drugs
NDV-3 vaccine
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on 2023-507527-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507527-28-00.